TY  - BOOK
AU  - Johnston,Melvin C.
AU  - Knight,Jerome E.
TI  - Septic shock: symptoms, management & risk factors 
T2  - Emergency and intensive care medicine
SN  - 9781622574995
AV  - RC182.S4 
U1  - 616.94 23
PY  - 2013///
CY  - Hauppauge, N.Y., Lancaster
PB  - Nova Science, Gazelle [distributor]
KW  - Septic shock
KW  - Shock, Septic
KW  - Choc infectieux
KW  - HEALTH & FITNESS
KW  - Diseases
KW  - Contagious
KW  - bisacsh
KW  - MEDICAL
KW  - Infectious Diseases
KW  - fast
KW  - Electronic books
N1  - SEPTIC SHOCK: SYMPTOMS, MANAGEMENT AND RISK FACTORS; SEPTIC SHOCK: SYMPTOMS, MANAGEMENT AND RISK FACTORS; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter 1: Pathophysiology of Cardiovascular Failure in Septic Shock; Abstract; Introduction; 1. Molecular Mechanisms in the Pathophysiology of Septic Shock; 1.1. Changes of Myocyte ion Transport by Inflammatory Mediators; Calcium Channels; Potassium Channels; 1.3. Changes in Cytoskeletal Proteins; 1.3. Mitochondrial Dysfunction in Septic Shock; 1.4. The Role of Endotoxins and Bacterial Virulence Factors in Septic ShockEndotoxin; Effects of other Bacterial Toxins; 2. Microcirculation in Septic Shock; 3. Myocardial Dysfunction in Septic Shock; 3.1. The role of Cytokines in Myocardial Dysfunction; 3.2. Myocardial Cell Death; 3.2.1. The Role of Poly(Adenosine 5'-diphosphate-ribose); Polymerase Activation; 3.2.2. The Role of Nitric Oxide; 4. Pathophysiology of Inotrope Refractory Cardiovascular Failure; Conclusion; References; Chapter 2: Sepsis and Septic Shock: Risk Factors, Symptoms and Management; Abstract; Introduction; Risk Factors; DefinitionsPathogenesis; Symptoms; Management; Early Management; Ongoing Management; Recommendations; References; Chapter 3: Septic Shock: Clinical Diagnosis and Risk Factors; Abstract; Abbreviations; 1. Introduction; 1.1. Basic Concepts; 1.2. Epidemiological Impact of Sepsis and Septic Shock; 2. Clinical Approach to the Septic Patient; 2.1. Suspected Sepsis in the ER; 2.2. Patients at Risk of Septic Shock; 2.3. Confirming the Diagnosis; 2.3.1. Laboratory Analyses and Work-Up; 2.3.2. Imaging Studies; 2.3.3. New Diagnostic Tools and Future Research; 2.3.3.1. Inflammatory Biomarkers; 2.3.3.2. Oxidative Stress BiomarkersConclusion; References; Chapter 4: Diagnosis and Management of Life-Threatening Infections and Septic Shock During Idiopathic Drug-Induced Agranulocytosis; Abstract; Introduction; Criteria for the Definition of Idiopathic Drug-Induced Agranulocytosis; Epidemiology of Agranulocytosis; Incriminated Drugs in Idiopathic Agranulocytosis; Clinical Manifestations of Drug-Induced Neutropenia and Agranulocytosis; Differential Diagnosis of Acute Neutropenia; Prognosis and Mortality Rate of Drug Induced Agranulocytosis, Frailty Patients; Management of Drug-Induced Severe Neutropenia or AgranulocytosisPrevention; General Measures; Indications of Antimicrobial Agents; Indications of Hematopoietic Growth Factors; Conclusion; References; Chapter 5: Sepsis: A Disease of the Microcirculation; Abstract; Introduction; Microcirculation; The Shunting Theory of Sepsis; Monitoring the Microcirculation; Nailfold videocapillaroscopy; Laser Doppler; Orthogonal Polarization Spectral; and Sidestream Dark Field Imaging; Near-Infrared Spectroscopy; The Microcirculation in Sepsis; Sepsis and Outcome; Vasopressors and Inotropes; Norepinephrine
UR  - https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=541984
ER  -